Press release, February 4, 2025
We, who are endocrinologists, cardiologists, and nephrologists, know well the efficacy of GLP-1 receptor agonist (GLP-1 RA) therapy in weight loss and improving cardiovascular diseases risk factors
The obtained good 2D classes were used for template-based automatic particle picking, and false positives or bad particles were subsequently eliminated over two rounds of 2D classification, resulting in 9101 selected particles
This is especially important for individuals with diabetes, as any supplement claiming metabolic effects requires medical oversight to ensure it does not interfere with established treatment regimens or mask concerning symptoms requiring evaluation
Retatrutide, as a triple agonist (GLP-1R + GIPR + GCGR) , is hypothesised to build on these benchmarks by adding the thermogenic and lipolytic effects attributed to glucagon receptor activation